<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35587030</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1460-2369</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>18</Day>
            </PubDate>
          </JournalIssue>
          <Title>Human reproduction update</Title>
          <ISOAbbreviation>Hum Reprod Update</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ovarian stimulation strategies for intrauterine insemination in couples with unexplained infertility: a systematic review and individual participant data meta-analysis.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">dmac021</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/humupd/dmac021</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Intrauterine insemination with ovarian stimulation (IUI-OS) is a first-line treatment for unexplained infertility. Gonadotrophins, letrozole and clomiphene citrate (CC) are commonly used agents during IUI-OS and have been compared in multiple aggregate data meta-analyses, with substantial heterogeneity and no analysis on time-to-event outcomes. Individual participant data meta-analysis (IPD-MA) is considered the gold standard for evidence synthesis as it can offset inadequate reporting of individual studies by obtaining the IPD, and allows analyses on treatment-covariate interactions to identify couples who benefit most from a particular treatment.</AbstractText>
          <AbstractText Label="OBJECTIVE AND RATIONALE" NlmCategory="OBJECTIVE">We performed this IPD-MA to compare the effectiveness and safety of ovarian stimulation with gonadotrophins, letrozole and CC and to explore treatment-covariate interactions for important baseline characteristics in couples undergoing IUI.</AbstractText>
          <AbstractText Label="SEARCH METHODS" NlmCategory="METHODS">We searched electronic databases including MEDLINE, EMBASE, CENTRAL, CINAHL, and PsycINFO from their inception to 28 June 2021. We included randomized controlled trials (RCTs) comparing IUI-OS with gonadotrophins, letrozole and CC among couples with unexplained infertility. We contacted the authors of eligible RCTs to share the IPD and established the IUI IPD-MA Collaboration. The primary effectiveness outcome was live birth and the primary safety outcome was multiple pregnancy. Secondary outcomes were other reproductive outcomes, including time to conception leading to live birth. We performed a one-stage random effects IPD-MA.</AbstractText>
          <AbstractText Label="OUTCOMES" NlmCategory="RESULTS">Seven of 22 (31.8%) eligible RCTs provided IPD of 2495 couples (62.4% of the 3997 couples participating in 22 RCTs), of which 2411 had unexplained infertility and were included in this IPD-MA. Six RCTs (n = 1511) compared gonadotrophins with CC, and one (n = 900) compared gonadotrophins, letrozole and CC. Moderate-certainty evidence showed that gonadotrophins increased the live birth rate compared to CC (6 RCTs, 2058 women, RR 1.30, 95% CI 1.12-1.51, I2 = 26%). Low-certainty evidence showed that gonadotrophins may also increase the multiple pregnancy rate compared to CC (6 RCTs, 2058 women, RR 2.17, 95% CI 1.33-3.54, I2 = 69%). Heterogeneity on multiple pregnancy could be explained by differences in gonadotrophin starting dose and choice of cancellation criteria. Post-hoc sensitivity analysis on RCTs with a low starting dose of gonadotrophins (≤75 IU) confirmed increased live birth rates compared to CC (5 RCTs, 1457 women, RR 1.26, 95% CI 1.05-1.51), but analysis on only RCTs with stricter cancellation criteria showed inconclusive evidence on live birth (4 RCTs, 1238 women, RR 1.15, 95% CI 0.94-1.41). For multiple pregnancy, both sensitivity analyses showed inconclusive findings between gonadotrophins and CC (RR 0.94, 95% CI 0.45-1.96; RR 0.81, 95% CI 0.32-2.03, respectively). Moderate certainty evidence showed that gonadotrophins reduced the time to conception leading to a live birth when compared to CC (6 RCTs, 2058 women, HR 1.37, 95% CI 1.15-1.63, I2 = 22%). No strong evidence on the treatment-covariate (female age, BMI or primary versus secondary infertility) interactions was found.</AbstractText>
          <AbstractText Label="WIDER IMPLICATIONS" NlmCategory="CONCLUSIONS">In couples with unexplained infertility undergoing IUI-OS, gonadotrophins increased the chance of a live birth and reduced the time to conception compared to CC, at the cost of a higher multiple pregnancy rate, when not differentiating strategies on cancellation criteria or the starting dose. The treatment effects did not seem to differ in women of different age, BMI or primary versus secondary infertility. In a modern practice where a lower starting dose and stricter cancellation criteria are in place, effectiveness and safety of different agents seem both acceptable, and therefore intervention availability, cost and patients' preferences should factor in the clinical decision-making. As the evidence for comparisons to letrozole is based on one RCT providing IPD, further RCTs comparing letrozole and other interventions for unexplained infertility are needed.</AbstractText>
          <CopyrightInformation>© The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wessel</LastName>
            <ForeName>J A</ForeName>
            <Initials>JA</Initials>
            <Identifier Source="ORCID">0000-0002-0232-5015</Identifier>
            <AffiliationInfo>
              <Affiliation>Amsterdam UMC location University of Amsterdam, Centre for Reproductive Medicine, Department of Obstetrics and Gynaecology, Amsterdam Reproduction and Development Research Institute, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Danhof</LastName>
            <ForeName>N A</ForeName>
            <Initials>NA</Initials>
            <AffiliationInfo>
              <Affiliation>Amsterdam UMC location University of Amsterdam, Centre for Reproductive Medicine, Department of Obstetrics and Gynaecology, Amsterdam Reproduction and Development Research Institute, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van Eekelen</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0002-9045-3630</Identifier>
            <AffiliationInfo>
              <Affiliation>Amsterdam UMC location University of Amsterdam, Centre for Reproductive Medicine, Department of Obstetrics and Gynaecology, Amsterdam Reproduction and Development Research Institute, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Diamond</LastName>
            <ForeName>M P</ForeName>
            <Initials>MP</Initials>
            <Identifier Source="ORCID">0000-0001-6353-4489</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Augusta University, Augusta, GA 30912, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Legro</LastName>
            <ForeName>R S</ForeName>
            <Initials>RS</Initials>
            <Identifier Source="ORCID">0000-0001-9927-7584</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Penn State College of Medicine, Hershey, PA 17033, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peeraer</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0002-5646-7799</Identifier>
            <AffiliationInfo>
              <Affiliation>UZ Leuven, Leuven University Fertility Center, Leuven 3000, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>D'Hooghe</LastName>
            <ForeName>T M</ForeName>
            <Initials>TM</Initials>
            <Identifier Source="ORCID">0000-0002-2373-8257</Identifier>
            <AffiliationInfo>
              <Affiliation>Merck Healthcare KGaA, Darmstadt 64293, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Development and Regeneration, Group Biomedical Sciences, KU Leuven/University of Leuven, Leuven 3000, Belgium.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Yale University, New Haven, CT 06520, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Erdem</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, Department of Obstetrics &amp; Gynecology, Gazi University, Ankara 06560, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dankert</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Rijnstate Hospital Arnhem, 06560 Ankara, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cohlen</LastName>
            <ForeName>B J</ForeName>
            <Initials>BJ</Initials>
            <Identifier Source="ORCID">0000-0003-1405-7780</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynaecology, Isala Fertility Center, 8025 AB Zwolle, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thyagaraju</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of OBG, Jawaharlal Institute of Postgraduate Medical education and Research (JIPMER), Pondicherry 605006, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mol</LastName>
            <ForeName>B W J</ForeName>
            <Initials>BWJ</Initials>
            <Identifier Source="ORCID">0000-0001-8337-550X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynaecology, Monash University, Clayton, VIC 3168, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Aberdeen Centre for Women's Health Research, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen AB24 3FX, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Showell</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-1227-4303</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynaecology, University of Auckland, Auckland 1142, New Zealand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van Wely</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-8263-213X</Identifier>
            <AffiliationInfo>
              <Affiliation>Amsterdam UMC location University of Amsterdam, Centre for Reproductive Medicine, Department of Obstetrics and Gynaecology, Amsterdam Reproduction and Development Research Institute, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mochtar</LastName>
            <ForeName>M H</ForeName>
            <Initials>MH</Initials>
            <AffiliationInfo>
              <Affiliation>Amsterdam UMC location University of Amsterdam, Centre for Reproductive Medicine, Department of Obstetrics and Gynaecology, Amsterdam Reproduction and Development Research Institute, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>R</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0002-6622-8134</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynaecology, Monash University, Clayton, VIC 3168, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Hum Reprod Update</MedlineTA>
        <NlmUniqueID>9507614</NlmUniqueID>
        <ISSNLinking>1355-4786</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">clomiphene citrate</Keyword>
        <Keyword MajorTopicYN="N">gonadotrophins</Keyword>
        <Keyword MajorTopicYN="N">individual participant data</Keyword>
        <Keyword MajorTopicYN="N">intrauterine insemination</Keyword>
        <Keyword MajorTopicYN="N">letrozole</Keyword>
        <Keyword MajorTopicYN="N">meta-analysis</Keyword>
        <Keyword MajorTopicYN="N">ovarian stimulation</Keyword>
        <Keyword MajorTopicYN="N">unexplained infertility</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>5</Hour>
          <Minute>22</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35587030</ArticleId>
        <ArticleId IdType="doi">10.1093/humupd/dmac021</ArticleId>
        <ArticleId IdType="pii">6588517</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
